MK-3655 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Nov 11, 2020 → Apr 13, 2023
NCT ID
NCT04583423About MK-3655 + Placebo
MK-3655 + Placebo is a phase 2 stage product being developed by Merck for Nonalcoholic Steatohepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04583423. Target conditions include Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04583423 | Phase 2 | Terminated |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis